Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 1,310,000 shares, a growth of 6.5% from the October 31st total of 1,230,000 shares. Currently, 4.0% of the shares of the stock are short sold. Based on an average trading volume of 683,000 shares, the short-interest ratio is presently 1.9 days.

Institutional Investors Weigh In On Werewolf Therapeutics

Hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new stake in Werewolf Therapeutics in the 3rd quarter worth about $29,000. Point72 DIFC Ltd acquired a new stake in shares of Werewolf Therapeutics during the second quarter valued at approximately $34,000. XTX Topco Ltd purchased a new stake in shares of Werewolf Therapeutics during the third quarter worth $45,000. Rhumbline Advisers bought a new position in shares of Werewolf Therapeutics in the second quarter valued at approximately $79,000. Finally, American Century Companies Inc. grew its holdings in shares of Werewolf Therapeutics by 50.7% during the 2nd quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock worth $92,000 after purchasing an additional 12,656 shares in the last quarter. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Stock Down 2.0 %

HOWL stock opened at $1.96 on Tuesday. Werewolf Therapeutics has a one year low of $1.58 and a one year high of $8.19. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10. The firm has a 50-day simple moving average of $2.19 and a two-hundred day simple moving average of $2.59.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a report on Tuesday, November 19th.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.